SCHEMBL25538733

SCHEMBL25538733

CSc1ncc2c(n1)N(C1CC1)C(=O)NC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
FGFR4 P22455 2/20 0.37
PIM1 P11309 4/20 0.35
PIM2 Q9P1W9 4/20 0.35
TTK P33981 3/20 0.35
MAPK14 Q16539 1/20 0.32
PDE9A O76083 1/20 0.31
RPS6KA5 O75582 1/20 0.31
PIK3CA P42336 1/20 0.31
MTOR P42345 1/20 0.31
PDE4B Q07343 1/20 0.31
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3971277 0.95 MEN1 (0.44) MEN1KMT2AKDM4EMAPTTHRB
SCHEMBL29714346 0.95 MEN1 (0.44) MEN1KMT2AKDM4EMAPTTHRB
SCHEMBL29714341 0.95 MEN1 (0.44) MEN1KMT2AKDM4EMAPTTHRB
SCHEMBL3971391 0.82 HCAR1 (0.34) FGFR4ADORA2A
SCHEMBL31139435 0.80 FGFR4 (0.48) MEN1KMT2AKDM4EMAPTFGFR4
SCHEMBL3967401 0.80 FGFR4 (0.48) MEN1KMT2AKDM4EMAPTFGFR4
SCHEMBL24170053 0.78 FGFR4 (0.34) MEN1KMT2AKDM4EMAPTTHRB
SCHEMBL25538730 0.78 FGFR4 (0.35) MEN1KMT2AKDM4EMAPTTHRB
SCHEMBL22419389 0.77 MEN1 (0.38) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL30278827 0.77 FGFR4 (0.38) MEN1KMT2AFGFR4PIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174550-A1 IDH MUTANT INHIBITOR AND USE THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2023-06-08 US disclosed
US-20230174550-A1 IDH MUTANT INHIBITOR AND USE THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174550-A1 IDH MUTANT INHIBITOR AND USE THEREOF IDH1, IDH3A, IDH3B MEN1 1178/4885KMT2A 335/4885KDM4E 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.